Abstract:In the management of acute major vessel occlusion, the use of fibrinolytic agents such as recombinant tissue plasminogen activator (rt-PA), urokinase or streptokinase is widely accepted. Today, the spectrum of indications for thrombolytic drugs comprises acute myocardial infarction, lung embolism, ischaemic stroke, deep vein thrombosis and acute arterial occlusions of the lower limbs. In view of the histopathological and clinical features of retinal vessel occlusion, fibrinolysis aimed at early restoration of blood flow appears to be a promising therapeutic approach. Basically, it is of some concern that the systemic administration of fibrinolytic agents is associated with a haemorrhagic risk. Since this includes cerebral haemorrhage or gastrointestinal bleeding, the choice of an appropriate intravenous thrombolytic therapy in a non-life threatening situation such as central retinal artery occlusion (CRAO) or central retinal vein occlusion (CRVO) should be based on minimising the risk of adverse events. Furthermore, the fibrinolytic treatment of choice should be able to produce rapid and complete restoration of retinal capillary and arterial or venous blood flow and maintain patency long enough for retinal salvage to take place. In this article, we review several studies of fibrinolytic therapy in patients with retinal vessel occlusion to determine whether this treatment is likely to improve major clinical outcomes. Moreover, we review the large scale trials of fibrinolysis in myocardial infarction and acute ischaemic stroke to evaluate safety and efficacy of various thrombolytic regimens. Furthermore, we report on our results of fibrinolytic therapy with low dose rt-PA in patients with retinal artery occlusion and ischaemic central retinal vein occlusion. In light of the fact that the occurrence of bleeding complications constitutes a dose dependent problem, we conclude that the use of low dose regimens should be the ideal approach to fibrinolysis in retinal vessel occlusion. Although the results of our pilot studies must be interpreted with caution, we believe that the administration of low-dose rt-PA (50 mg) in a frontloaded manner (= simultaneous administration of rt-PA and intravenous heparin) constitutes a reasonable treatment option in patients with central retinal artery occlusion (CRAO) or ischaemic retinal vein occlusion (RVO), recent onset of symptoms (CRAO < or = 12 h, RVO < or = 11 d) and severe visual loss (< or = 20/50). Because of these limitations and the numerous contraindications of fibrinolytic therapy, only a limited number of patients will be suitable for this treatment. In view of the poor visual and ocular prognosis in severe retinal vessel occlusion, controlled clinical trials are needed to determine the benefit of thrombolysis in the management of this disease.

An Evaluation Method for Content Analysis Based on Twitter Content Influence

Efficacy of Intra-Arterial Thrombolysis for Acute Central Retinal Artery Occlusion: A Meta-Analysis.

Fragments of MS2 RNA as messengers for specific bacteriophage proteins: fragments from fluorouracil-containing particles.

Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion

Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a randomized, controlled trial

Is Intravenous Thrombolysis Safe and Effective in Central Retinal Artery Occlusion? A Critically Appraised Topic

Synthsis and antitumor properties of bis(quinaldine) derivatives.

Thrombolysis in central retinal artery occlusion: a retrospective observational study

Midwifery and family practice.

IV Thrombolysis for Central retinal artery occlusion – real-world experience from a Comprehensive Stroke Center

Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!

Early REperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION): Study Protocol of a Phase III Trial

Acute central retinal artery occlusion treated with intravenous recombinant tissue plasminogen activator

[Systemic lysis therapy in retinal vascular occlusions]

Galanin‐ and CGRP‐like immunoreactivity coexist in rat spinal motoneurons

Targeted next generation sequencing reveals a novel intragenic deletion of the LAMA2 gene in a patient with congenital muscular dystrophy.

Nationwide Incidence and Trends in Central Retinal Arterial Occlusion Management: A 5000-Patient Analysis

GENETIC AND EXPERIMENTAL STUDIES ON A LETHAL FACTOR (R) IN THE AXOLOTL WHICH INDUCES ABNORMALITIES IN THE RENAL SYSTEM AND OTHER ORGANS.

Abstract WMP11: Intravenous Thrombolysis in Patients Without versus With Visible Occlusion: A Secondary Analysis From the AcT Trial

Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion

Minor Non-Disabling Stroke Patients with Large Vessel Severe Stenosis or Occlusion Might Benefit from Thrombolysis